CAMAGÜEY.- (PL) The collaboration between the Center for Genetic Engineering and Biotechnology (CIGB, Spanish acronym) and the University of Camagüey (UC) today allows an increase in the production of livestock in this central-eastern region of Cuba.

Studies related to the potential in the sector by specialists from both institutions make it possible for the peasantry of this province to apply medicines such as the Gavac, a recombinant anti-tick vaccine, created in the Camagüey´s CIGB.

Recently, specialists from the Center for Biotechnology participated in the 7th International Conference on Science and Technology for Sustainable Development, organized by UC, where the scientific community exchanged criteria of vital benefit for the Ministry of Agriculture of Cuba.

The results, far from being optimal, are accompanied by a promotional work and a training plan to different instances that allowed the GAVAC program apply doses to near 500 thousand specimens, according to data provided by the Department of Promotion of the CIGB, in its subsidiary Camagüey.

Events such as the International Congress BioProecess, celebrated this year in the territory, attest to the scientific advances in biotechnology in Cuba, where CIGB and UC researchers have a leading role.

For his part, the dean of the Faculty of Agricultural Sciences of the UC, Amílcar Arenal, explained that "the application of the results of other researches such as the program Effect of parasites on milk production, facilitates the epidemiological survey in herds of the region of Camagüey ".

In terms of equipment, the UC also benefited in the last two years from the collaboration project with the University of Ghent, Belgium, with a state-of-the-art laboratory that facilitates the analysis of certain parasites and bacteria that directly influence the quality of Dairy Products.

Founded on July 25, 1989 by Fidel Castro, the Center for Genetic Engineering and Biotechnology (CIGB) in Camagüey is capable of generating millions of dollars in the economy of the country, thanks to recognized medicines such as Heberprot-P, applied to more than 250 thousand patients from all over the world.

Translated by Ludys Peguero Domínguez/ 3rd year English Language student